Amgen publishes study assessing cost-effectiveness of Repatha; Brilinta reduces death in patients with heart-attack history; Roche drug gets priority review
Five things for pharma marketers to know: Tuesday, June 27, 2017
Cigna signs value contracts for new cholesterol drugs; Yelp partners with ProPublica for hospital reviews; ad-blocking threat to digital publishers intensifies
Eli Lilly’s failed trial could spell the end for CETP inhibitors
Express Scripts revises PCSK9 inhibitor projections; research points to benefits of osteoporosis drugs; doctors consider emotional toll of cancer costs
It’s possible that payers won’t prove the wild card in the PCSK9 derby. Instead, physician preference may do more to shape the market and maybe even force payers’ hands.
The pharmacy benefit manager included both PCSK9 inhibitors on its national formulary. Spending on the drugs is estimated to reach $750 million in 2016.
